NEW YORK, NY – Alpha Tau Medical, Inc. (NASDAQ: AOAT) today unveiled its groundbreaking new therapeutic approach, 'The Financial Loss Therapy,' following a GAAP EPS report of -$0.42. The company, previously focused on cancer treatments, announced that its latest innovation will instead focus on delivering a highly personalized, deeply impactful experience of monetary devaluation directly to patients.

“We’ve discovered that the human body, particularly the wallet, responds remarkably to consistent, predictable financial setbacks,” stated Dr. Evelyn Thorne, Alpha Tau’s newly appointed Chief Emotional Drain Officer. “Our -$0.42 EPS wasn't a failure; it was a proof-of-concept. We're simply scaling up a highly effective, albeit unconventional, form of intervention.”

The new therapy involves a series of proprietary financial instruments designed to systematically erode personal wealth, culminating in a profound sense of market-induced despair. Early trials, inadvertently conducted on the company's own investors, showed a 100% success rate in achieving significant emotional distress and a newfound appreciation for the concept of 'zero.'

“Patients will receive a bespoke portfolio of highly volatile, speculative assets, meticulously curated to ensure maximum underperformance,” explained Thorne. “We guarantee a deeply immersive experience of financial anxiety, followed by the liberating acceptance of having nothing left to lose.” The company anticipates strong demand from individuals seeking to preemptively experience economic downturns or simply wanting a unique form of self-flagellation. Analysts are reportedly 'confused but intrigued' by the new business model, noting its potential to corner the burgeoning 'existential dread' market.